Captrust Financial Advisors Fate Therapeutics Inc Transaction History

Captrust Financial Advisors

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 16, 2022	BUY	$17.78 - $42.39 $8,267 - $19,711	465 Added 5166.67%	474 $12,000
Q1 2022 May 16, 2022	SELL	$29.67 - $60.28 $1,216 - $2,471	-41 Reduced 82.0%	9 $0
Q4 2021 Feb 14, 2022	BUY	$47.84 - $64.34 $1,196 - $1,608	25 Added 100.0%	50 $3,000
Q3 2021 Nov 16, 2021	SELL	$59.27 - $95.73 $2,252 - $3,637	-38 Reduced 60.32%	25 $1,000
Q2 2021 Aug 16, 2021	SELL	$67.25 - $92.52 $807 - $1,110	-12 Reduced 16.0%	63 $5,000
Q1 2021 May 17, 2021	BUY	$72.16 - $117.4 $5,412 - $8,805	75 New	75 $6,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $222M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.